Diagnostic and prognostic testing for Solid Tumours

The Bristol Genetics Laboratory offers an expanding repertoire of pharmacogenetic tests for Solid Tumours for a range of tumour types. Molecular analysis of solid tumour DNA is useful for confirming diagnosis, assessing prognosis and for guiding therapeutic decisions. This stratified or personalised medicine approach is becoming increasingly important in the treatment and management of patients with solid tumours. Our laboratory offers state-of-the-art clinical molecular testing for a range of clinically actionable genes in a variety of tumour types.


The following services are currently offered:


• EGFR mutation analysis in non-small cell lung cancer (NSCLC)
• ALK rearrangements in NSCLC
• BRAF codon 600 mutation analysis for metastatic melanoma and hairy cell leukaemia
• KRAS/NRAS mutation analysis in metastatic colorectal cancer
• 1p and 19q co-deletion analysis in gliomas
• MGMT promoter methylation in gliomas
• IDH1 and IDH2 in gliomas
• BRAF fusion in gliomas
• KIT and PDGFRA in Gastrointestinal Stromal Tumours (GIST)


Please contact the laboratory if the above tests are required on tumour types that differ to those listed

 

Last Updated 12th Oct 2017